Skip to main content

Table 4 Comparison of outcomes between the mPSL alone and rTM groups after the stabilised IPTW

From: Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

  Odds ratiob 95% CI p value
Logistic regression analyses of patients in the rTM and mPSL alone groups after the stabilised IPTW
 All patients
  In-hospital mortality 1.15 0.71–1.84 0.57
  14-day mortality 0.80 0.48–1.32 0.38
  28-day mortality 0.79 0.53–1.19 0.26
  Bleeding eventsa 1.60 0.70–3.64 0.27
 Survivors
  Bleeding eventsa 0.33 0.04–2.68 0.30
  Incidence rate ratioc 95% CI p value
Incidence rate ratios of length of hospital stay in the rTM and mPSL alone groups after the stabilised IPTW
 All patients
  Length of hospital stay 1.18 0.93–1.50 0.18
 Survivors
  Length of hospital stay 1.34 0.95–1.92 0.098
  1. rTM recombinant human soluble thrombomodulin, mPSL methylprednisolone, IPTW inverse probability of treatment weighting, CI confidence interval
  2. aBleeding events included epistaxis, hemoptysis, pulmonary hemorrhage, subcutaneous hemorrhage, purpura, muscle hemorrhage, hematuria, gastrointestinal bleeding, bloody stool and intracranial hemorrhage
  3. bThe odds ratio of the rTM group compared to the mPSL alone group
  4. cThe incidence rate ratio of the rTM group compared to the mPSL alone group